Prognostic impact of plasma lipids in patients with lower respiratory tract infections-An observational study

Swiss Medical Weekly

Volumn 139, Issue 11-12, 2009, Pages 166-172

  Gruber, Maja ^a   Christ Crain, Mirjam ^a   Stolz, Daiana ^a   Keller, Ulrich ^a   Müller, Christian ^a   Bingisser, Roland ^a   Tamm, Michael ^a   Mueller, Beat ^a,b   Schuetz, Philipp ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Cholesterol; Lipid levels; Pneumonia; Prognosis; Sepsis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STEROID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BACTEREMIA; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LIPID BLOOD LEVEL; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE;

EID: 64549108944     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bonville DA, Parker TS, Levine DM, Gordon BR, Hydo LJ, Eachempati SR, et al. The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with systemic inflammatory response syndrome. Surg Infect. (Larchmt) 2004;5:39-49.
2. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med. 1996;24:584-9.
3. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med. 2001;29:1563-8.
4. Luthold S, Berneis K, Bady P, Muller B. Effects of infectious disease on plasma lipids and their diagnostic significance in critical illness. Eur J Clin Invest. 2007;37:573-9.
5. Vermont CL, den Brinker M, Kakeci N, de Kleijn ED, de Rijke YB, Joosten KF et al. Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med. 2005;33:1610-5.
6. Gui D, Spada PL, De Gaetano A, Pacelli F. Hypocholesterolemia and risk of death in the critically ill surgical patient. Int Care Med. 1996;22:790-4.
7. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002;162:1059-64.
8. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10.
9. Stolz D, Christ-Crain M, Gencay MM, Bingisser R, Huber PR, Muller B, et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly. 2006; 136:434-40.
10. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600-7.
11. Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P, et al. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC family practice 2005;6:34.
12. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84-93.
13. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007; 131:9-19.
14. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC health services research 2007;7:102.
15. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-54.
16. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
17. Calverley PM and Walker P. Chronic obstructive pulmonary disease. Lancet. 2003;362:1053-61.
18. Gonzales R, Sande MA. Uncomplicated acute bronchitis. Ann Intern Med. 2000;133:981-91.
19. von Elm E, Airman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies. Gaceta sanitaria /S.E.S.P.A 2008;22:144-50.
20. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644-55.
21. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
22. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-82.
23. Giovannini I, Boldrini G, Chiarla C, Giuliante F, Vellone M, Nuzzo G. Pathophysiologic correlates of hypocholesterolemia in critically ill surgical patients. Intensiv Care Med. 1999;25:748-51.
24. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med. 2003;3 1:1359-66.
25. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993;90:12040-4.
26. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005;24:16-31.
27. Levels JH, Abraham PR, van Barreveld EP, Meijers JC, van Deventer SJ. Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun. 2003;71:3280-4.
28. Levels JH, Abraham PR, van den Ende A, van Deventer SJ. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun. 2001;69:2821-8.
29. Akgun S, Ertel NH, Mosenthal A, Oser W. Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med. 1998;131:103-8.
30. Fraunberger P, Schaefer S, Werdan K, Walli At, Seidel D. Reduction of circulating cholesterol and apolipoprotein levels during sepsis. Clin Chem Lab Med. 1999;37:357-62.
31. Murch O, Collin M, Hinds CJ, Thiemermann C. Lipoproteins in inflammation and sepsis. I. Basic science. Intensiv Care Med. 2007;33:13-24.
32. Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia.Am J Respir Crit Care Med. 2004;169:342-7.
33. Muller B, Schuetz P, Trampuz A. Circulating biomarkers as surrogates for bloodstream infections. Int J Antimicrob Agents. 2007.
34. Schuetz P, Christ-Crain M, Muller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care. 2007;13:578-85.
35. Muller B, Suess E, Schuetz P, Muller C, Bingisser R, Bergmann A, et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med. 2006;260:568-76.
36. Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R, et al. Circulating levels of copeptin, a novel bio-marker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37:145-52.
37. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C. Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care. (London, England) 2006;10:R96.
38. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-54.
39. Lopez-Martinez J, Sanchez-Castilla M, Garcia-de-Lorenzo A. Hvpocholesterolemia in critically ill patients. Intensiv Care Med. 2000;26:259-60.
40. Muller B, Christ-Crain M, Schuetz P. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis. 2007;7:498-9;author reply 502-3.